Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | LHCGR | P22888 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022934 | 0.91 | CFTR (0.44) | CFTRFAAHNPY5RKMT2AHTR2A | |
| SCHEMBL3022685 | 0.91 | NPY5R (0.43) | CFTRFAAHNPY5RPDGFRBKMT2A | |
| SCHEMBL3012867 | 0.90 | NPY5R (0.49) | CFTRFAAHNPY5RMEN1KMT2A | |
| SCHEMBL3028509 | 0.87 | LHCGR (0.40) | CFTRFAAHPDGFRBKMT2AHTR2A | |
| SCHEMBL3022138 | 0.86 | NPY5R (0.45) | CFTRFAAHNPY5RKMT2AHTR2A | |
| SCHEMBL3026842 | 0.85 | FAAH (0.42) | CFTRFAAHNPY5RPAX8HTR2A | |
| SCHEMBL3023429 | 0.82 | LHCGR (0.40) | CFTRFAAHNPY5RKMT2AHTR2A | |
| SCHEMBL3018805 | 0.78 | NAMPT (0.53) | PAX8 | |
| SCHEMBL3023606 | 0.77 | NAMPT (0.43) | CFTRFAAH | |
| SCHEMBL3028365 | 0.77 | HRH3 (0.44) | MEN1KMT2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | SCN1B, SCN2B, SCN1A | CFTR 866/4885FAAH 597/4885NPY5R 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.